Drug profile · INN
lefamulin acetate
XENLETA
lefamulin acetate (XENLETA) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — lefamulin acetate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lefamulin acetate (XENLETA) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lefamulin acetate?
lefamulin acetate (XENLETA) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lefamulin acetate?
XENLETA is a marketed brand name for lefamulin acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lefamulin acetate?
lefamulin acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.